Efficacy, Efficiency, and Safety of En-bloc vs Three-lobe Enucleation of the Prostate: A Propensity Score-matched Analysis.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
05 2023
Historique:
received: 07 12 2022
revised: 25 01 2023
accepted: 07 02 2023
medline: 2 6 2023
pubmed: 25 2 2023
entrez: 24 2 2023
Statut: ppublish

Résumé

To assess efficacy, efficiency, and safety in holmium laser enucleation of the prostate (HoLEP), we directly compared intraoperative performance, postoperative outcomes, and safety in the original 3-lobe enucleation technique with the more recent en-bloc method. As HoLEP is widely accepted as a size-independent method for surgical treatment of patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO), detailed understanding of its benefits is mandatory. We conducted a retrospective, propensity score-matched analysis of 1,396 men who underwent HoLEP for LUTS/BPO between 2017 and 2020. We included 606 patients in the final analysis (en-bloc n = 303; 3-lobe n = 303), who were matched for prostate size (50 cc), age, body mass index, and preoperative international prostate symptom score. Patients were then stratified by technique, and groups were compared for perioperative parameters, safety, and short-term functional outcomes. While postoperative symptoms and urodynamic parameters improved irrespective of technique, we report significantly less adverse events (Clavien-Dindo classification ≥II vs <II) for patients receiving en-bloc enucleation. Additionally, en-bloc enucleation was more efficient, that is, less than half of total laser energy (kJ), twice shorter enucleation time, and surgical performance (g/kJ/min) significantly increased 4-fold with prostate volume, compared to 3-lobe enucleation. While HoLEP in general is a safe and effective procedure, en-bloc enucleation techniques offer better surgical performance.

Identifiants

pubmed: 36828266
pii: S0090-4295(23)00172-3
doi: 10.1016/j.urology.2023.02.014
pii:
doi:

Substances chimiques

Holmium W1XX32SQN1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

48-55

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Alexander Tamalunas (A)

Department of Urology, University Hospital, LMU Munich, Munich, Germany. Electronic address: alexander.tamalunas@med.uni-muenchen.de.

Melanie Schott (M)

Department of Urology, University Hospital, LMU Munich, Munich, Germany.

Patrick Keller (P)

Department of Urology, University Hospital, LMU Munich, Munich, Germany.

Michael Atzler (M)

Department of Urology, University Hospital, LMU Munich, Munich, Germany.

Benedikt Ebner (B)

Department of Urology, University Hospital, LMU Munich, Munich, Germany.

Martin Hennenberg (M)

Department of Urology, University Hospital, LMU Munich, Munich, Germany.

Christian G Stief (CG)

Department of Urology, University Hospital, LMU Munich, Munich, Germany.

Giuseppe Magistro (G)

Department of Urology, University Hospital, LMU Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH